In contrast, neutropenia occurs relatively frequently during the IL-6R blocker therapy (with a frequency of 29% and 33% in two randomized controlled trials (RCTs) [16,25], but high-grade neutropenia or significant infectious events are rare. This evidence concerns the gene IL6R and Decreased total neutrophil count.